WO2011065335A1 - Agent de prévention ou d'amélioration de l'hypersensibilité pour peau sensible - Google Patents

Agent de prévention ou d'amélioration de l'hypersensibilité pour peau sensible Download PDF

Info

Publication number
WO2011065335A1
WO2011065335A1 PCT/JP2010/070830 JP2010070830W WO2011065335A1 WO 2011065335 A1 WO2011065335 A1 WO 2011065335A1 JP 2010070830 W JP2010070830 W JP 2010070830W WO 2011065335 A1 WO2011065335 A1 WO 2011065335A1
Authority
WO
WIPO (PCT)
Prior art keywords
sensitive skin
extract
preventing
hypersensitivity
skin
Prior art date
Application number
PCT/JP2010/070830
Other languages
English (en)
Japanese (ja)
Inventor
かつら 森
浩 野尻
正 中村
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 花王株式会社 filed Critical 花王株式会社
Priority to CN201080053487XA priority Critical patent/CN102665673A/zh
Publication of WO2011065335A1 publication Critical patent/WO2011065335A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9755—Gymnosperms [Coniferophyta]
    • A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Definitions

  • the present invention relates to an agent for preventing and improving hypersensitivity for sensitive skin.
  • nerve growth factor (NGF) production inhibitors are known as sensitive skin improving agents.
  • nerve growth factor (NGF) production inhibitors containing, as active ingredients, Japanese cypress, common mother, birch, mugwort and the like (patented) Literature 1) and nerve growth factor production inhibitors (Patent Literature 2) composed of eugenol glycoside, isoeugenol glycoside, raspberry ketone glycoside, rhododendrol glycoside and the like are known.
  • the present invention provides an agent for preventing and improving hypersensitivity for sensitive skin, comprising asunalo or an extract thereof as an active ingredient.
  • the present invention also provides a composition containing asunalo or an extract thereof used for preventing and improving hypersensitivity of sensitive skin.
  • the present invention also provides a method for preventing and improving sensitivity perception of sensitive skin, characterized by applying a composition containing asunalo or an extract thereof to patients with sensitive skin.
  • this invention provides use of the composition containing asnalo or its extract for manufacture of the hypersensitivity prevention improvement agent for sensitive skin.
  • the present invention provides the use of a composition containing asunalo or an extract thereof for improving the prevention of hypersensitivity for sensitive skin.
  • Asnalo which is an active ingredient of the present invention, or an extract thereof, can prevent or improve hypersensitive symptoms in sensitive skin without changing the expression level of nerve growth factor (NGF).
  • NGF nerve growth factor
  • Asunaro or an extract thereof has been widely used for medicinal purposes since ancient times, and has high safety.
  • Nerve growth factor is known to increase in production at inflammatory sites such as atopic dermatitis and cause hyperalgesia, etc., but at the same time, secrete physiologically active substances involved in skin regeneration. Since it also has an accelerating action, it may not be preferable to suppress this expression, particularly when it is easy to recognize sensory stimuli even though it does not cause excessive inflammation or immune response. Accordingly, an object of the present invention is to provide an agent for preventing and improving hypersensitivity that is effective in preventing and improving hypersensitive symptoms in sensitive skin that does not change the expression level of nerve growth factor (NGF) and that makes it easy to recognize sensory stimulation. There is to do.
  • the present inventors have extensively studied the pharmacological action of plant extracts in order to solve the above-mentioned problems, and the perception of sensitive asthma in the extract of asunaro does not change the expression level of nerve growth factor (NGF).
  • NGF nerve growth factor
  • asunaro which is an active ingredient of the agent for improving and preventing hypersensitivity for sensitive skin of the present invention
  • antimicrobial action As for the physiological activity of asunaro, which is an active ingredient of the agent for improving and preventing hypersensitivity for sensitive skin of the present invention, antimicrobial action, whitening action, bone disease prevention action, cell adhesion inhibitory action, antiallergic action, immunosuppressive action, anti-inflammatory
  • NGF nerve growth factor
  • the asunalo extract used in the present invention is obtained by extracting all or a portion of asunalo with a solvent.
  • the asunal part include a leaf part and a twig part. More specifically, the leaves, twigs, etc. of Asunaro are pulverized without drying or drying, and then extracted with a solvent at room temperature or under heating, or using an extraction device such as a Soxhlet extractor. Can be obtained.
  • the asnalaro extract in this invention shall mean various solvent extracts, its dilution liquid, a concentrate, or a dry powder.
  • the solvent extract is obtained by using all or part of asnalo or a dry powder thereof as water, organic solvent (hydrocarbon solvents such as petroleum ether, n-hexane, cyclohexane, toluene, benzene; dichloromethane, chloroform, carbon tetrachloride).
  • organic solvent hydrocarbon solvents such as petroleum ether, n-hexane, cyclohexane, toluene, benzene; dichloromethane, chloroform, carbon tetrachloride.
  • Halogenated hydrocarbons such as: ether solvents such as diethyl ether; ester solvents such as ethyl acetate; ketones such as acetone; basic solvents such as pyridine; butanol, propanol, ethanol, methanol, polyethylene glycol, propylene glycol And monohydric or polyhydric alcohol solvents such as butylene glycol), aqueous alcohol, etc., and usually by extraction at 3 to 70 ° C.
  • the above extract can be used as it is as an active ingredient of the present invention.
  • the extract is highly active by appropriate separation means such as gel filtration, silica gel column chromatography, high performance liquid chromatography, etc.
  • the fraction can also be fractionated and used.
  • the above asunalo extract can be used as it is, or after diluting, concentrating or lyophilizing it, preparing it in a powder form or a paste form, and formulating it appropriately. Moreover, it can also be used after performing purification treatment such as deodorization and decolorization using activated carbon or the like, if necessary.
  • the extract can be applied to the skin without causing irritation to sensitive skin by removing ethanol by a method such as solvent substitution and using it as a polyhydric alcohol solution.
  • a polyhydric alcohol solution is preferable because the effect of the active ingredient can be sufficiently exhibited.
  • the polyhydric alcohol include diols such as ethylene glycol, polyethylene glycol (average molecular weight 1000 or less), propylene glycol, dipropylene glycol, butylene glycol (1,3-butylene glycol); 3 to 3 such as glycerin and diglycerin. A tetravalent alcohol is mentioned. Of these, diols such as propylene glycol, dipropylene glycol and 1,3-butylene glycol are preferred.
  • the content of the polyhydric alcohol is preferably 0.02 to 50% by mass, more preferably 2 to 20% by mass in the agent for preventing and improving hypersensitivity for sensitive skin of the present invention.
  • the content of ethanol in the agent for improving and preventing hypersensitivity for sensitive skin of the present invention is preferably less than 8% by mass, more preferably less than 4% by mass, further preferably less than 1% by mass, and particularly substantially ethanol. It is preferable not to contain.
  • the sensitive skin refers to a hypersensitive state in which nerve fibers are easily perceived by elongating into the epidermis and immediately below the stratum corneum, causing excessive inflammation and immune reaction. It is distinguished from allergic conditions that are present and diseased skin such as atopic dermatitis. Specifically, because the sensory nerves are sensitive, they are easily affected by slight external stimuli (temperature, humidity, dust, allergens, etc.), and the use of cosmetics and external stimuli can cause tingling, tingling, and itching.
  • nerve growth factor nerve growth factor
  • NGF nerve growth factor
  • the agent for preventing and improving hypersensitivity for sensitive skin according to the present invention which can prevent and ameliorate hypersensitive symptoms in sensitive skin without changing the expression level of nerve growth factor (NGF), is very preferable.
  • the agent for preventing and improving hypersensitivity for sensitive skin of the present invention is formulated into a composition of any form together with commonly used additives.
  • the content of asunalo extract in these preparations is preferably 0.0001 to 0.1% by mass, more preferably 0.01 to 0.1% by mass in terms of solid matter.
  • the solid conversion is a value converted based on the amount of solid obtained by drying 10 mL of the measurement sample at 105 ° C. for 6 hours.
  • the agent for preventing and improving hypersensitivity for sensitive skin includes surfactants, moisturizers, oils, thickeners, pigments and pigments incorporated in cosmetics, quasi-drugs, and pharmaceutical external preparations as necessary.
  • Salts, chelating agents, neutralizing agents, ultraviolet absorbers, preservatives, bactericides, purified water, natural water, deep ocean water, ethyl alcohol, and the like can be appropriately blended.
  • dosage forms include ointments, lotions, emulsions, creams, gels, packs, powders, aerosols, poultices, and the like.
  • the agent for preventing and improving hypersensitivity for sensitive skin of the present invention is more preferably applied to a predetermined part of the skin for a certain period or longer than a single application.
  • a composition containing 0.0001 to 0.1 wt% on solid basis the dolabrata extract, per 0.1mg / cm 2 ⁇ 5mg / cm 2 1 times The amount is preferably applied to the skin 1 to 5 times a day, 3 days or more, more preferably 1 week or more. Furthermore, one to three times the amount per 1mg / cm 2 ⁇ 3mg / cm 2 1 times a day, a week or more, more preferably for application to the skin for more than 10 days.
  • Reference example 1 (Asunaro extract manufacturing method) Asunaro's dried branches and leaves (about 1 kg) are chopped, soaked in ethanol (10 liters), extracted for 7 days with occasional stirring at room temperature, the obtained extract is filtered, and the filtrate is filtered at 5 ° C. After leaving still for days, it is filtered again to obtain a supernatant. To this, 9 times the amount of 50% 1,3-butylene glycol solution is added and filtered. The filtrate is concentrated, and 1,3-butylene glycol and purified water are further added thereto, followed by filtration once more to obtain a product (about 100 L). The obtained asnalo extract had a content of 1,3-butylene glycol of 54.75%, a water content of 45%, and a content of asnalo solids of 0.25%.
  • NGF nerve growth factor
  • Test Example 2 Effect on Current Sense Stimulus Threshold by Continuous Application of Asunaro Extract
  • a 1% lactic acid aqueous solution sting test was performed by the following method. Immediately after applying facial cleansing for 10 minutes after cleansing a subject who is not a disease skin such as allergic dermatitis such as atopic dermatitis, a 20 cm 2 non-woven fabric soaked with 1.2 mL of 1% lactic acid aqueous solution is applied to the cheek.
  • this drug improved the state of hypersensitivity because the entry of the nerve to the epidermis that was elongated by a factor other than the nerve growth factor (NGF) production inhibitor was suppressed.
  • NGF nerve growth factor
  • the measuring method of the electric current sense threshold value by a neurometer is as follows. ⁇ Measurement method of current sense threshold ⁇ When an electrode having a diameter of about 1 cm is attached to the cheek and an AC current of 250 Hz is applied using a neurotron manufactured by Neurotron, the current level at which the subject can perceive the stimulus is determined as a current perception threshold (CPT: Current Perception). Threshold).
  • CPT Current Perception
  • Test Example 3 Change in Lactic Acid Sting Score by Continuous Application of Asunalo Extract
  • a 4% aqueous solution of asunalo extract of Reference Example 1 was applied to 2 mg / cm 2 on one cheek 3 times a day for 2 weeks.
  • a 1% lactic acid aqueous solution sting test was carried out in the same manner as in Test Example 3 before and after continuous use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un agent de prévention ou d'amélioration de l'hypersensibilité pour peau sensible, qui peut être utilisé facilement et se révèle extrêmement sûr. Ledit agent de prévention ou d'amélioration de l'hypersensibilité pour peau sensible comprend, en tant que principe actif, du Thujopsis dolabrata ou un extrait de celui-ci.
PCT/JP2010/070830 2009-11-27 2010-11-22 Agent de prévention ou d'amélioration de l'hypersensibilité pour peau sensible WO2011065335A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201080053487XA CN102665673A (zh) 2009-11-27 2010-11-22 敏感性皮肤用知觉过敏预防改善剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009269677 2009-11-27
JP2009-269677 2009-11-27

Publications (1)

Publication Number Publication Date
WO2011065335A1 true WO2011065335A1 (fr) 2011-06-03

Family

ID=44066440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/070830 WO2011065335A1 (fr) 2009-11-27 2010-11-22 Agent de prévention ou d'amélioration de l'hypersensibilité pour peau sensible

Country Status (4)

Country Link
JP (1) JP2011132220A (fr)
CN (1) CN102665673A (fr)
TW (1) TW201121555A (fr)
WO (1) WO2011065335A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016222586A (ja) * 2015-05-29 2016-12-28 花王株式会社 頭皮用化粧料
RU2645110C1 (ru) * 2014-08-06 2018-02-15 Шисейдо Компани, Лтд. Исходный материал для косметических средств

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014210753A (ja) * 2013-04-22 2014-11-13 花王株式会社 アスナロエキスの製造方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09255546A (ja) * 1996-03-22 1997-09-30 Kao Corp 皮膚外用剤
JP2003081844A (ja) * 2001-09-11 2003-03-19 Kao Corp 皮膚刺激緩和剤
JP2004067581A (ja) * 2002-08-06 2004-03-04 Kao Corp Ｏ／ｗ乳化組成物の製造方法
JP2004339113A (ja) * 2003-05-14 2004-12-02 Ichimaru Pharcos Co Ltd ストレスによる肌荒れ予防改善剤
JP2005200395A (ja) * 2003-12-16 2005-07-28 Kao Corp 外用剤配合物
JP2009137915A (ja) * 2007-12-10 2009-06-25 Kao Corp 水中油型乳化化粧料
JP2009137914A (ja) * 2007-12-10 2009-06-25 Kao Corp 水中油型乳化化粧料
JP2009161520A (ja) * 2007-12-10 2009-07-23 Kao Corp 水中油型乳化化粧料

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0455546A (ja) * 1990-06-26 1992-02-24 Matsushita Electric Works Ltd 天井構造

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09255546A (ja) * 1996-03-22 1997-09-30 Kao Corp 皮膚外用剤
JP2003081844A (ja) * 2001-09-11 2003-03-19 Kao Corp 皮膚刺激緩和剤
JP2004067581A (ja) * 2002-08-06 2004-03-04 Kao Corp Ｏ／ｗ乳化組成物の製造方法
JP2004339113A (ja) * 2003-05-14 2004-12-02 Ichimaru Pharcos Co Ltd ストレスによる肌荒れ予防改善剤
JP2005200395A (ja) * 2003-12-16 2005-07-28 Kao Corp 外用剤配合物
JP2009137915A (ja) * 2007-12-10 2009-06-25 Kao Corp 水中油型乳化化粧料
JP2009137914A (ja) * 2007-12-10 2009-06-25 Kao Corp 水中油型乳化化粧料
JP2009161520A (ja) * 2007-12-10 2009-07-23 Kao Corp 水中油型乳化化粧料

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RITSUKO HAYAKAWA ET AL.: "Gosei Giji Ceramide Haigo Zenshin Lotion (K0401) no Yuyosei to Anzensei no Kento", GEKKAN RINSHO TO KENKYU, vol. 81, no. 12, 20 December 2004 (2004-12-20), pages 2039 - 2049 *
TOMOKO MINAGAWA ET AL.: "Clinical Evaluation of Skin Care Products Containing Thujopsis dolabrata var. hondae Extracts on Patients with Dry Skin", THE NISHINIHON JOURNAL OF DERMATOLOGY, vol. 71, no. 5, 1 October 2009 (2009-10-01), DEPARTMENT OF DERMATOLOGY, HIROSAKI UNIVERSITY GRADUATE SCHOOL OF MEDICINE, pages 512 - 516 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2645110C1 (ru) * 2014-08-06 2018-02-15 Шисейдо Компани, Лтд. Исходный материал для косметических средств
JP2016222586A (ja) * 2015-05-29 2016-12-28 花王株式会社 頭皮用化粧料

Also Published As

Publication number Publication date
JP2011132220A (ja) 2011-07-07
TW201121555A (en) 2011-07-01
CN102665673A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
KR101236946B1 (ko) 식물성 추출물을 포함하는 아토피 피부염 완화용 화장료 조성물
KR102309958B1 (ko) 구근추출물을 포함하는 피부 개선용 조성물
US20220218595A1 (en) Method of using soothing cream including maca root extract as an active ingredient
KR102410502B1 (ko) 로즈마리, 감국, 목련꽃, 호장근 추출물을 함유하는 항염, 항산화 효과를 갖는 화장료 조성물
KR102171133B1 (ko) 병풀 추출물 및 개양귀비 추출물을 포함하는 피부 외용제 조성물
CN113576966B (zh) 用于化妆品的组合物及其制备方法和应用
WO2011065335A1 (fr) Agent de prévention ou d'amélioration de l'hypersensibilité pour peau sensible
KR102189330B1 (ko) 구근추출물을 포함하는 피부 개선용 조성물
KR100513659B1 (ko) 식물 혼합 추출물을 함유하는 아토피 피부 개선용 화장료조성물
KR20210018388A (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR100638053B1 (ko) 소루쟁이 추출물을 유효성분으로 함유하는 피부자극 완화용화장료 조성물
KR20150112103A (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR101365204B1 (ko) 졸음운전 방지용 조성물
JP5562616B2 (ja) セマフォリン発現増強剤
JP6834084B2 (ja) ゲンチオピクロシドを含まないゲンチアナ抽出物
KR100816265B1 (ko) 대황 추출물을 유효성분으로 함유하는 피부자극 완화용화장료 조성물
JP5047511B2 (ja) 顆粒球・マクロファージコロニー刺激因子（ｇｍ−ｃｓｆ）産生抑制剤ｉ
KR101436819B1 (ko) 피부 보습, 진정 및 여드름 개선용 화장료 조성물
JP4579550B2 (ja) セラミド合成促進剤及び皮膚外用剤
KR101743001B1 (ko) 키토산 및 프로폴리스 추출물을 포함하는 화장료 조성물
JP5155543B2 (ja) エンドセリン−１産生抑制剤、ヘキソサミニダーゼ遊離抑制剤、抗炎症用／美白用皮膚外用剤、エンドセリン−１の産生抑制方法及びヘキソサミニダーゼの遊離抑制方法
KR20210024268A (ko) 병풀추출물, 세라마이드 및 자작나무수액을 포함하는 피부 자극 완화 및 피부 장벽 개선 효과의 화장료 조성물
KR102082580B1 (ko) 죽여 추출물의 안정화 방법 및 안정화된 죽여 추출물을 함유하는 화장료 조성물
KR100835093B1 (ko) 피부 알러지 완화 및 예방용 화장료 조성물
JP2019108278A (ja) しわ改善剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080053487.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10833181

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10833181

Country of ref document: EP

Kind code of ref document: A1